TY - JOUR T1 - Efficacy of Gemcitabine-based Chemotherapy in Clear Cell Sarcoma of Soft Tissue JF - Anticancer Research JO - Anticancer Res SP - 7003 LP - 7007 DO - 10.21873/anticanres.14725 VL - 40 IS - 12 AU - ELENA COJOCARU AU - KHIN THWAY AU - CYRIL FISHER AU - CHRISTINA MESSIOU AU - SHANE ZAIDI AU - AISHA B. MIAH AU - CHARLOTTE BENSON AU - SPYRIDON GENNATAS AU - PAUL HUANG AU - ROBIN L. JONES Y1 - 2020/12/01 UR - http://ar.iiarjournals.org/content/40/12/7003.abstract N2 - Background/Aim: Clear cell sarcoma (CCS) is an aggressive sarcoma subtype, resistant to conventional anthracycline-based chemotherapy and radiation. The diagnosis is often challenging due to similarities with malignant melanoma. Patients and Methods: We aimed to analyse the activity of gemcitabine-based chemotherapy in a cohort of patients with CCS treated at the Royal Marsden Hospital. Results: Five patients with metastatic CCS received gemcitabine as first- or second-line systemic therapy. The median time-to-progression was 10 weeks. The median number of cycles of gemcitabine-based therapy was 3 (range=2-7 cycles). Median overall survival in our cohort was 66 months from the initial diagnosis but in the metastatic setting, the overall survival was reduced to 28 months. Conclusion: Gemcitabine-based therapy has modest activity in CCS. There remains a significant unmet medical need for novel, effective therapies for this disease. ER -